Human leukocyte antigen class II molecules presenting programmed death-ligand 1-derived peptides (HLA-II/PD-L1 peptide complex)

Human leukocyte antigen (HLA) class II molecules presenting programmed death-ligand 1 (PD-L1)-derived peptides serve as a critical interface for the immune system to recognize and respond to immunosuppressive cells. PD-L1 is a protein often upregulated by tumor cells and myeloid-derived suppressor cells (MDSCs) to inhibit T-cell activity via the PD-1/PD-L1 pathway (Ahmad et al., 2014). Intracellular degradation of PD-L1 results in the generation of specific peptides that are loaded onto HLA class II molecules and displayed on the cell surface (Munir et al., 2013). These complexes are the primary targets for PD-L1-specific CD4+ T cells, which can directly lyse PD-L1-expressing cells or modulate the tumor microenvironment by secreting Th1-type cytokines. Therapeutic interventions, such as the peptide vaccine IO103, are designed to activate and expand these specific T-cell populations to enhance anti-tumor immunity (IO Biotech). By targeting the presentation of PD-L1 peptides, these therapies aim to reverse immune evasion and improve outcomes in various malignancies.

Other names

HLA-DR/PD-L1 peptide complexMHC class II/PD-L1 peptide complexPD-L1-derived peptide/HLA-II complexPD-L1 peptide-MHC II complex

The mechanism involves the activation of PD-L1-specific CD4+ T cells that recognize PD-L1 peptides presented by HLA class II molecules. These T cells then exert direct cytotoxic effects on PD-L1-expressing tumor cells and immunosuppressive cells, while also releasing pro-inflammatory cytokines like interferon-gamma to stimulate a broader anti-tumor immune response (Ahmad et al., 2014; Munir et al., 2013).